Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antaitavir hasophate
- Development stage
- Phase 3
- Lead developer
- Sunshine Lake Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Antaitavir hasophate is an orally administered small molecule drug developed for the treatment of chronic hepatitis C virus (HCV) infection. It acts as an inhibitor of the nonstructural protein 5A (NS5A), a key viral protein involved in HCV replication. The drug is being evaluated both as monotherapy and in combination with other antivirals such as yiqibuvir. Clinical trials have reached phase III, focusing on its efficacy and safety in adult patients with chronic hepatitis C. The primary developer is Sunshine Lake Pharma, a subsidiary of HEC Pharm[1][2][3][4][7].
- Brand names
- antaitavir hasophate
- Other names
- netanasvir phosphateantaitavir hasophateHEC74647PAHEC-74647PAHEC 74647PAHEC 74647 PAHEC74647 PAHEC-74647 PA
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on antaitavir hasophate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antaitavir hasophate.